



December 20, 2016

Novartis Pharma AG
CH-4002, Basel, Switzerland

Reference: EudraCT 2011-005316-28/ Novartis Protocol ID CBGG492A2214

A multi-center, randomized, double-blind, parallel group, placebo controlled, study in patients with non-chronic migraine to assess the efficacy, safety and tolerability of BID oral doses of BGG492 in migraine prevention

Trial CBGG492A2214 was cancelled with no patient enrollment and as such, no results will be reported.